The agency brought action against Caremark, Express Scripts and Optum Rx on Friday, arguing their “anticompetitive and unfair” rebating practices “artificially inflated” the list price of life-saving insulin drugs.
The agency brought action against Caremark, Express Scripts and Optum Rx on Friday, arguing their “anticompetitive and unfair” rebating practices “artificially inflated” the list price of life-saving insulin drugs.